Car T-Cell Therapy

Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.

The FDA has approved an investigational new drug application for Kyverna Therapeutics’ KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for diffuse cutaneous systemic sclerosis, according to a company press release.

Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with systemic sclerosis, according to a press release from its manufacturer.

SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.

First and foremost, I want to remind you that this is an editorial, which by definition offers an “opinion,” so I don’t want to be pilloried for overstating data or brandishing irrational enthusiasm.

It is not often that a single data set has the potential to fundamentally alter the treatment landscape for a disease in rheumatology, but recent findings on the use of chimeric antigen receptor T-cells in lupus may eventually do just that.

The FDA announced several regulatory actions the past few weeks.